UK markets closed

Medtronic plc (MDT)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
123.23-1.98 (-1.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close125.21
Open123.59
Bid123.31 x 1400
Ask124.99 x 1000
Day's range123.19 - 124.33
52-week range87.68 - 132.30
Volume5,820,593
Avg. volume4,689,725
Market cap165.794B
Beta (5Y monthly)0.80
PE ratio (TTM)46.33
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.52 (2.02%)
Ex-dividend date24 Jun 2021
1y target estN/A
All
News
  • Medtronic to Acquire Medicrea
    Business Wire

    Medtronic to Acquire Medicrea

    Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of spinal surgery through artificial intelligence, predictive modeling and patient specific implants, today announced that they have entered into a tender offer agreement for the acquisition of all outstanding shares of Medicrea. The friendly voluntary all-cash tender offer will be at a price of €7.00 per Medicrea share (the "Tender Offer"). The Boards of Directors of both companies have unanimously approved the transaction.

  • Medtronic and Tandem Diabetes Care Enter Into Patent Cross-License Agreement
    Business Wire

    Medtronic and Tandem Diabetes Care Enter Into Patent Cross-License Agreement

    Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.